When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Axicabtagene ciloleucel - Wikipedia

   en.wikipedia.org/wiki/Axicabtagene_ciloleucel

   Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. [8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor .

3. FDA says cancer treatment CAR-T therapy may increase ... - AOL

   www.aol.com/news/fda-says-cancer-treatment-car...

   Since then, another five have been approved. The makers of the drugs — Bristol Myers Squibb, for Abecma and Breyanzi; Gilead Sciences' Kite Pharma, for Yescarta and Tecartus; Johnson & Johnson's ...

4. Kite Pharma - Wikipedia

   en.wikipedia.org/wiki/Kite_Pharma

   Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]

5. Gilead’s Kite Receives FDA Approval For Yescarta ... - AOL

   www.aol.com/news/gilead-kite-receives-fda...

   Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The therapy is a first-of-its-kind treatment for adult ...

6. US FDA seeks 'boxed warning' for CAR-T cancer therapies - AOL

   www.aol.com/news/us-fda-requires-boxed-warning...

   (Reuters) -The U.S. health regulator on Monday asked a host of drugmakers, including Gilead Sciences, Johnson & Johnson and Novartis, to add a serious warning on the label of their cancer ...

7. CAR T cell - Wikipedia

   en.wikipedia.org/wiki/CAR_T_cell

   These trials ultimately led in the US to the FDA's first two approvals of CAR T cells in 2017, those for tisagenlecleucel (Kymriah), marketed by Novartis originally for B-cell precursor acute lymphoblastic leukemia (B-ALL), and axicabtagene ciloleucel (Yescarta), marketed by Kite Pharma originally for diffuse large B-cell lymphoma (DLBCL). [15]

8. Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA ... - AOL

   www.aol.com/news/gileads-gild-car-t-cell...

   For premium support please call: 800-290-4726 more ways to reach us

9. Tisagenlecleucel - Wikipedia

   en.wikipedia.org/wiki/Tisagenlecleucel

   Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...